Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
“As far as we know, immunotherapy on its own would not make patients more susceptible to COVID-19."
Clinical trials are looking at new therapeutic opportunities and at ways to boost the effectiveness of current immunotherapy treatments.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
We’re all familiar with vaccines that prime the immune system to prevent infections. Can a similar approach be used to fight cancer?
Immune modulator demonstrated an overall response rate of 52%
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
“If you have the opportunity to be part of something that helps others, why wouldn’t you at least try it?”
The reference meeting for scientists, clinicians, regulators, drug developers, and patient advocates.
Immunotherapy may prolong survival compared with standard chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.